233 related articles for article (PubMed ID: 23652475)
1. Therapy and clinical trials.
Sodhi N; Krasuski RA
Curr Opin Lipidol; 2013 Jun; 24(3):281-2. PubMed ID: 23652475
[No Abstract] [Full Text] [Related]
2. Winner by points?--LDL cholesterol as a target for therapeutic intervention.
Tietge UJ
Curr Opin Lipidol; 2013 Jun; 24(3):277-8. PubMed ID: 23652473
[No Abstract] [Full Text] [Related]
3. [Antibodies in addition to statin therapy lowers LDL cholesterol].
Bossenmayer S
Dtsch Med Wochenschr; 2012 Sep; 137(36):1728. PubMed ID: 23281534
[No Abstract] [Full Text] [Related]
4. PCSK9 inhibitors.
Farnier M
Curr Opin Lipidol; 2013 Jun; 24(3):251-8. PubMed ID: 23652470
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of PCSK9: is this the way forward for managing residual risk?
Chowdhury SR; Rees A
Curr Opin Lipidol; 2012 Oct; 23(5):509-10. PubMed ID: 22964999
[No Abstract] [Full Text] [Related]
6. [Effective LDL cholesterol reduction for high risk patients].
Einecke D
MMW Fortschr Med; 2016 Apr; 158(8):84. PubMed ID: 27116175
[No Abstract] [Full Text] [Related]
7. Dyslipidaemia in 2015: Advances in treatment of dyslipidaemia.
Grundy SM
Nat Rev Cardiol; 2016 Feb; 13(2):74-5. PubMed ID: 26763537
[No Abstract] [Full Text] [Related]
8. Cardiovascular endocrinology in 2012: PCSK9-an exciting target for reducing LDL-cholesterol levels.
Betteridge DJ
Nat Rev Endocrinol; 2013 Feb; 9(2):76-8. PubMed ID: 23296165
[TBL] [Abstract][Full Text] [Related]
9. [PCSK9 inhibition--A new era in cholesterol treatment].
Olsson A
Lakartidningen; 2015 Feb; 112():. PubMed ID: 25689006
[TBL] [Abstract][Full Text] [Related]
10. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
11. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
[TBL] [Abstract][Full Text] [Related]
12. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. A new drug class for the treatment of hypercholesterolemia.
Ortega Martínez de Victoria E
Endocrinol Diabetes Nutr; 2017; 64(7):341-344. PubMed ID: 28745604
[No Abstract] [Full Text] [Related]
13. [PCSK9 inhibitors: new treatment to lower cholesterol].
Gencer B; Rodondi N; Mach F
Rev Med Suisse; 2016 Mar; 12(508):440-2, 444. PubMed ID: 27089600
[TBL] [Abstract][Full Text] [Related]
14. [New drug development competition for LDL receptor].
Fujita T
Nihon Yakurigaku Zasshi; 2014 May; 143(5):262. PubMed ID: 24813799
[No Abstract] [Full Text] [Related]
15. [PCSK9 inhibitors - new possibilities in the treatment of hypercholesterolemia: For which patients will be indicated?Czech atherosclerosis society statement].
Soška V; Vrablík M; Bláha V; Cífková R; Češka R; Freiberger T; Kraml P; Piťha J; Rosolová H; Štulc T; Vaverková H; Urbanová Z
Vnitr Lek; 2016 Apr; 62(4):329-33. PubMed ID: 27250613
[TBL] [Abstract][Full Text] [Related]
16. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
Reiner Z
Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
[TBL] [Abstract][Full Text] [Related]
17. PCSK9 inhibition: the next statin?
Vogel RA
J Am Coll Cardiol; 2012 Jun; 59(25):2354-5. PubMed ID: 22465426
[No Abstract] [Full Text] [Related]
18. Alirocumab (Praluent) to lower LDL-Cholesterol.
Med Lett Drugs Ther; 2015 Aug; 57(1475):113-5. PubMed ID: 26262881
[No Abstract] [Full Text] [Related]
19. Normalization of low-density lipoprotein receptor expression in receptor defective homozygous familial hypercholesterolemia by inhibition of PCSK9 with alirocumab.
Lambert G; Chatelais M; Petrides F; Passard M; Thedrez A; Rye KA; Schwahn U; Gusarova V; Blom DJ; Sasiela W; Marais AD
J Am Coll Cardiol; 2014 Dec; 64(21):2299-300. PubMed ID: 25456764
[No Abstract] [Full Text] [Related]
20. [PCSK9 inhibitors: emerging treatment to lower cholesterol?].
Gencer B; Rodondi N; Mach F
Rev Med Suisse; 2014 Mar; 10(420):539-42, 544. PubMed ID: 24701672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
